Patents Assigned to UNIVERSITÉ D'AVIGNON
  • Patent number: 11448656
    Abstract: The present invention concerns a composition comprising at least three peptides derived from Mycobacterium tuberculosis antigen Rv2626c, its use in the diagnostic of latently infected Mycobacterium tuberculosis (LTBI) subjects, corresponding methods of use and kits.
    Type: Grant
    Filed: July 17, 2018
    Date of Patent: September 20, 2022
    Assignees: CNRS, CONICET, INSTITUT JEAN PAOLI & IRENE CALMETES, UNIVERSITE D' AIX-MARSEILLE, INSERM
    Inventors: Juan Iovanna, Virginia Pasquinelli, Maria Madgalena Gherardi, Hector Eduardo Chuluyan, Ana Inès Rovetta, Delfina Pena, Véronica Edith Garcia
  • Publication number: 20220283070
    Abstract: The present description relates according to a first aspect to a method for measurement of optical properties of at least one particle in a sample (10) and permits, for example, quantitative determination of the complex dipolar polarizability of at least one particle present in a sample. The optical characterization method comprises the illumination of said sample (10) using a light beam, the sample (10) being positioned in the object space of an optical system (120); the acquisition of at least one phase image and at least one intensity image of said at least one particle illuminated by the light beam, the acquisition being carried out in an analysis plane arranged in the image space of the optical system (120); and the determination of at least one optical property of said at least one particle from said at least one phase image and at least one intensity image.
    Type: Application
    Filed: August 26, 2020
    Publication date: September 8, 2022
    Applicants: Centre National dela Recherche Scientifique, Université d'Aix-Marseille, CENTRALE MARSEILLE
    Inventors: Samira Khadir, Guillaume Baffou, Serge Monneret
  • Publication number: 20220280655
    Abstract: Adeno-associated virus (AAV) is a defective mono-stranded DNA virus, endemic in human population (35-80%). Recurrent clonal AAV2 insertions are associated with the pathogenesis of rare human hepatocellular carcinoma (HCC) developed on normal liver. The aimed of the inventors was to characterize the natural history of AAV infection in the liver. Viral DNA was thus quantified in tumor and non-tumor liver tissues of 1461 patients. Presence of episomal form and viral mRNA expression were analyzed using a DNAse/TaqMan based assay and quantitative RT-PCR. In silico analyses using viral capture data explored viral variants and new clonal insertions. AAV DNA was detected in 21% of the patients equally distributed in 2 major viral subtypes: one similar to AAV2, the other hybrid between AAV2 and AAV13 sequences. Thus the inventors provided an integrated analysis of the wild type AAV infection in the liver with the identification of viral genotypes, molecular forms, helper virus relationship and viral integrations.
    Type: Application
    Filed: April 23, 2020
    Publication date: September 8, 2022
    Applicants: Institut National de la Santé et de la Recherche Médicale, Assistance Publique-Hôpitaux de Paris, Genethon, Sorbonne Université, Universite de Paris, Université d'Evry-Val-d'Essonne, Universite Paris XIII Paris-Nord Villetaneuse
    Inventors: Jessica Zucman-Rossi, Jean-Charles Nault, Tiziana La Bella, Giuseppe Ronzitti, Sandrine Imbeaud, Patrice Vidal
  • Publication number: 20220273582
    Abstract: A continuous process for nano-emulsification that is performed by concentration phase inversion in a microfluidic reactor, including the following steps: (a) injection of an aqueous phase into a first microchannel, the first microchannel opening onto a formulation chamber, (b) injection, into a second microchannel, of a fatty phase including one or more fatty substances immiscible in the aqueous phase, and one or more surfactants, the second microchannel opening into the formulation chamber, then (c) mixing of the aqueous phase and the fatty phase in the formulation chamber, then (d) recovering, at the output of the formulation chamber, a suspension including lipid nanocapsules. Also, the lipid nanocapsules obtainable by the process, and the use of the lipid nanocapsules as nanovectors for pharmacologically active ingredients.
    Type: Application
    Filed: July 24, 2020
    Publication date: September 1, 2022
    Applicants: UNIVERSITÉ D'ANGERS, INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Brice CALVIGNAC, Jean-Christophe GIMEL, Emilie ROGER, Nicolas ROLLEY, Guillaume LEFEBVRE, Guillaume BASTIAT, Florian FOUCHET, Kévin MATHA
  • Publication number: 20220273850
    Abstract: A three-dimensional biomaterial including particles encapsulating at least one complement active fragment dispersed therein. Also, a process of manufacturing of the three-dimensional biomaterial with at least one biocompatible and/or resorbable polymer and the particles. The three-dimensional biomaterial is useful for tissue regeneration, especially with regards to dental pulp, dentin, periodontal and gingival tissues, as well as bones tissues.
    Type: Application
    Filed: July 31, 2020
    Publication date: September 1, 2022
    Applicants: SEPTODONT OU SEPTODONT SAS OU SPECIALITES SEPTODONT, UNIVERSITÉ D'AIX MARSEILLE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Imad ABOUT, Gilles RICHARD, Madison BERGMANN, Charlotte JEANNEAU, Mounir DJOUDI
  • Patent number: 11427648
    Abstract: The present invention relates to the field of diagnostic and treatment of cancer, particularly melanoma, pancreatic cancer, kidney cancer and colon cancer. In particular, the invention relates to an antibody directed specifically to CD146-positive tumors and its applications, particularly for use as a medicament for the prevention and/or treatment of cancer, for use in a method of diagnostic or prognostic of a cancer, or for use as a radiotracer when labelled with a radioactive element.
    Type: Grant
    Filed: October 5, 2018
    Date of Patent: August 30, 2022
    Assignees: UNIVERSITE D'AIX-MARSEILLE, ASSISTANCE PUBLIQUE HÔPITAUX DE MARSEILLE, INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE)
    Inventors: Marcel Blot-Chabaud, Benjamin Guillet, Marie Nollet, Jimmy Stalin, Nathalie Bardin, Françoise Dignat-George
  • Patent number: 11428924
    Abstract: According to one aspect, the invention relates to a device for transporting and controlling light beams for endo-microscopic imaging without a lens on the distal side comprising a single-mode optical fibre bundle (40) on the distal side, wherein each single-mode optical fibre is intended to receive an elementary light source and to emit a light beam at a distal end; a single-mode optical fibre section (50) arranged at the distal end of the optical fibre bundle and intended to receive the light beams emitted by the single-mode optical fibres of the optical fibre bundle; an optical phase control device arranged on the side of the proximal end of the single-mode optical fibres.
    Type: Grant
    Filed: April 4, 2017
    Date of Patent: August 30, 2022
    Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE—CNRS, Ecole Centrale de Marseille (ECM), Université d'Aix-Marseille (AMU)
    Inventors: Hervé Rigneault, Esben Ravn Andresen, Siddarth Sivankutty
  • Patent number: 11427836
    Abstract: An RNA interference (RNAi) strategy is provided based on use of artificial microRNA (amiR) to reduce NKCC1 expression. In particular, a method is provided that achieves neuron-specific expression of specific amiR against NKCC1 by using a human Synapsin promoter to drive transgene expression.
    Type: Grant
    Filed: April 11, 2018
    Date of Patent: August 30, 2022
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE, UNIVERSITE D'EVRY-VAL-D'ESSONNE, GENETHON, FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA, FONDAZIONE TELETHON
    Inventors: Federico Mingozzi, Giuseppe Ronzitti, Andrea Contestabile, Laura Cancedda
  • Publication number: 20220266505
    Abstract: The method for manufacturing a three-dimensional object or for modifying the surface state of a preformed object by local polymerisation of monomers or oligomers, the polymerisation being initiated by mono-photon or multi-photon absorption in an area to be polymerised, includes: —introducing into a vessel with light-transparent walls a reaction medium comprising polymerisable monomers or oligomers, a polymerisation inhibitor, an indicator of the amount of the inhibitor and a photochemical polymerisation initiator; —initiating the polymerisation of the monomers or oligomers; —indicating the amount of inhibitor present in the reaction medium; —controlling the amount of light emitted by the irradiation system relative to the amount of inhibitor indicated by the indicator; and —switching to a following zone to be polymerised by moving the object and/or the focused light beam.
    Type: Application
    Filed: July 22, 2020
    Publication date: August 25, 2022
    Applicants: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), UNIVERSITE D'AIX-MARSEILLE (AMU), ECOLE CENTRALE DE MARSEILLE
    Inventors: Claude Amra, Jean-Claude André, Laurent Gallais-During, Myriam Zerrad
  • Publication number: 20220262515
    Abstract: The method for determining an onset time and an excitability of a brain region that is not observed as recruited or not recruited in a seizure activity of an epileptic patient brain includes: providing a dynamical model of a propagation of an epileptic seizure in the brain networks; providing a statistical model which defines the probability of generating sets of observations of the state of the brain networks by said dynamical model; training the dynamical model of the propagation of an epileptic seizure using the statistical model and the data set of observations of the training cohort; and inverting the trained dynamical model and inferring the onset time and excitability of a third region from the onset time that is observed for the first and second regions using the statistical model.
    Type: Application
    Filed: July 22, 2020
    Publication date: August 18, 2022
    Applicants: UNIVERSITÉ D'AIX-MARSEILLE (AMU), INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE
    Inventors: Viktor Jirsa, Viktor Sip
  • Publication number: 20220251232
    Abstract: Novel anti-CD25 antibodies and antigen-bind fragments thereof that do not inhibit the binding of interleukin-2 (IL-2) to CD25, and the use thereof for treating cancer or an infectious disease. Also, fusion proteins including the antibodies and antigen-bind fragments, nucleic acids encoding the antibodies and antigen-bind fragments, and an expression vectors including the nucleic acids. Further, pharmaceutical compositions including the fusion proteins or the antibodies and antigen-bind fragments.
    Type: Application
    Filed: May 20, 2020
    Publication date: August 11, 2022
    Applicants: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), INSTITUT JEAN PAOLI & IRENE CALMETTES, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITÉ D'AIX MARSEILLE, UNIVERSITE DE PARIS, ALDERAAN BIOTECHNOLOGY, UNIVERSITE PARIS EST CRETEIL VAL DE MARNE
    Inventors: Daniel OLIVE, Armand BENSUSSAN, Jérôme GIUSTINIANI, Arnaud FOUSSAT
  • Publication number: 20220249167
    Abstract: The method of identifying a potentially surgically operable target zone in an epileptic patient's brain includes: providing a computerized platform modelling various zones of a primate brain and connectivity between said zones; providing a model of an epileptogenic zone and a model of the propagation of an epileptic discharge from an epileptic zone to a propagation zone; obtaining a patient's personalized computerized platform; deriving the potential target zones based on modularity analysis; evaluating the target zones' effectiveness by simulating epileptic seizures propagation in the personalized patient's computerized platform; evaluating the target zones' safety by simulating spatiotemporal brain activation patterns in a defined state condition and comparing the simulated spatiotemporal brain activation patterns obtained before removal of the target zone with the spatiotemporal brain activation patterns obtained after removal of the target zone; identifying the target zones which satisfy both effectivenes
    Type: Application
    Filed: May 27, 2020
    Publication date: August 11, 2022
    Applicants: UNIVERSITÉ D'AIX-MARSEILLE (AMU), INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE
    Inventors: Sora An, Viktor Jirsa
  • Patent number: 11384351
    Abstract: The present invention relates to the field of nucleic acid purification. In particular, it relates to methods and tools for purifying nucleic acids in a sample; which are compatible with high-throughput sequencing and diagnosis. The inventors have shown that nucleic acid binding proteins recruited to polymerized tubulin (i.e. microtubules) could, subsequently, be isolated from cell lysates. Surprisingly, it has now been found that the amount of recovered nucleic acid found in these microtubule pellets increases dramatically in the presence of nucleic acid-trapping proteins comprising a nucleic acid-binding moiety and a polymerized tubulin-binding moiety, by comparison to proteins devoid of the nucleic acid-binding moiety; and that the recovery of the purified nucleic acids was itself particularly efficient. This purification method is particularly amenable to high-throughput sequencing and/or in the context of a diagnosis method for identifying or comparing the amount of nucleic acids in a set of samples.
    Type: Grant
    Filed: July 27, 2018
    Date of Patent: July 12, 2022
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE D'EVRY—VAL D'ESSONE
    Inventors: David Pastre, Bénédicte Desforges, Alexandre Maucuer
  • Patent number: 11384167
    Abstract: The present invention relates to compositions thermally curable on demand by red to near infrared irradiation, method of using same for thermal amplification of free radical polymerizations, and articles obtained by such method. The invention also relates to the use of a heat-generating dye in association with a thermal initiator for controlling the onset of thermal free radical polymerization.
    Type: Grant
    Filed: December 20, 2018
    Date of Patent: July 12, 2022
    Assignees: UNIVERSITE DE HAUTE-ALSACE, UNIVERSITE D'AIX-MARSEILLE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Aude-Heloise Bonardi, Jacques Lalevee, Fabrice Morlet-Savary, Celine Dietlin, Didier Gigmes, Frederic Dumur
  • Patent number: 11371061
    Abstract: The present invention relates to peptides and compositions for use in improving transduction efficiency of viruses into target cells.
    Type: Grant
    Filed: November 30, 2016
    Date of Patent: June 28, 2022
    Assignees: GENETHON, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE D'EVRY VAL D'ESSONNE
    Inventors: Saliha Majdoul, David Fenard
  • Patent number: 11351226
    Abstract: Cytoablative treatments lead to severe damages on thymic epithelial cells (TECs), which result in delayed de novo thymopoïesis and a prolonged period of T-cell immunodeficiency. Understanding the mechanisms that govern thymic regeneration is of paramount interest for the recovery of a functional immune system notably after bone marrow transplantation (BMT). Here, the inventors show that administration of RANK ligand (RANKL) after total body irradiation and BMT boosts thymic regeneration. Notably, this treatment is also beneficial upon BMT in aged individuals. The inventors show that RANKL can improve thymopoiesis in aged individuals affected by thymic involution. Finally, the inventors show that RANK receptor is conserved in the human thymus. Accordingly, one aspect of the present invention relates to a method of boosting thymic regeneration in a patient suffering from a thymic injury comprising administering to the subject a therapeutically effective amount of a RANKL polypeptide.
    Type: Grant
    Filed: February 26, 2018
    Date of Patent: June 7, 2022
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE D'AIX MARSEILLE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)
    Inventors: Magali Irla, Noella Lopes
  • Patent number: 11339406
    Abstract: The present invention relates to variants of acid-alpha glucosidase and uses thereof.
    Type: Grant
    Filed: September 12, 2017
    Date of Patent: May 24, 2022
    Assignees: GENETHON, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE D'EVRY VAL D'ESSONNE
    Inventors: Federico Mingozzi, Giuseppe Ronzitti
  • Publication number: 20220146710
    Abstract: A method for manufacturing an optical metasurface is configured to operate in a given working spectral band. The method comprises: obtaining a 2D array of patterns, each comprising one or more nanostructures forming dielectric elements that are resonant in said working spectral band, said nanostructures being formed in at least one photosensitive dielectric medium; exposing said 2D array to a writing electromagnetic wave having at least one wavelength in said photosensitivity spectral band, said writing wave having a spatial energy distribution in a plane of the 2D array that is a function of an intended phase profile, so that each pattern of the 2D array produces on an incident electromagnetic wave having a wavelength in the working spectral band, a phase variation corresponding to a refractive index variation experienced by said pattern during said exposure.
    Type: Application
    Filed: February 14, 2020
    Publication date: May 12, 2022
    Applicants: Université D'Aix-Marseille, Centre National de la Recherche Scientifique, Ecole Centrale de Marseille, Multiwave Innovation
    Inventors: Elena Mikheeva, Redha Abdeddaim, Stefan Enoch, Julien Lumeau, Ivan Voznyuk, Tryfon Antonakakis
  • Patent number: 11298348
    Abstract: Sarcoglycanopathies are autosomal recessive diseases caused by mutations in the one of the genes coding for any sarcoglycans (SG). The inventors previously showed that the application of small molecules developed to rescue ?F508-CFTR trafficking, and known as CFTR correctors, improved the maturation of several ?-sarcoglycan mutants that were consequently rescued at the plasma membrane (WO 014086687). Now, the inventors show that some specific CFTR correctors provide additive and even synergic effect when administered in combination.
    Type: Grant
    Filed: January 10, 2019
    Date of Patent: April 12, 2022
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MÉDICALE), UNIVERSITE D'EVRY-VAL-D'ESSONNE, GENETHON, UNIVERSITA 'DEGLI STUDI DI PADOVA
    Inventors: Isabelle Richard, Dorianna Sandona
  • Publication number: 20220102160
    Abstract: An etching method includes: a physical adsorption process of physically adsorbing an adsorbate based on a first processing gas on a film to be etched under a condition that the pressure of the first processing gas is smaller than the saturated vapor pressure of the first processing gas with respect to a temperature of an object to be processed while cooling the object to be processed on which the film to be etched is formed; and an etching process of etching the film to be etched by reacting the adsorbate with the film to be etched by a plasma of a second processing gas.
    Type: Application
    Filed: December 10, 2021
    Publication date: March 31, 2022
    Applicants: Tokyo Electron Limited, UNIVERSITE D'ORLEANS
    Inventors: Shigeru TAHARA, Jacques FAGUET, Kaoru MAEKAWA, Kumiko ONO, Nagisa SATO, Remi DUSSART, Thomas TILLOCHER, Philippe LEFAUCHEUX, Gaëlle ANTOUN